Stockscreener 앱 받기
2.85
5.17%
0.14
Abcellera Biologics Inc 주식(ABCL)의 최신 뉴스
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 3.3%Still a Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap UpHere's What Happened - MarketBeat
Walleye Capital LLC Makes New $668,000 Investment in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (FRA:8QQ) Price-to-Owner-Earnings : (As of Dec. 07, 2024) - GuruFocus.com
PDT Partners LLC Sells 173,884 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year By Investing.com - Investing.com Canada
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year - Investing.com India
AbCellera Biologics (FRA:8QQ) Degree of Operating Leverage : -1.44 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Debt : $3.95 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Pre-Tax Income : $-202.17 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Capex-to-Revenue : 2.85 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Buildings And Improvements : $66.92 Mil (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Revenue per Share : $0.11 (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Change In Receivables : $-64.70 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Debt-to-Equity : 0.07 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Owner Earnings per Share (TTM) : -0.61 (As of Sep. 2024) - GuruFocus.com
AbCellera to Present at Upcoming Investor Conferences in December and January - Devon Dispatch
AbCellera to Present at Major Healthcare Conferences: Piper Sandler and JPM 2024-25 - StockTitan
ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Bloom Burton Cuts Earnings Estimates for AbCellera Biologics - MarketBeat
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat
AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment - StockTitan
AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Earnings call: AbCellera reports steady Q3 2024 revenue amidst R&D growth - Investing.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Developments - GuruFocus.com
AbCellera Reports Q3 2024 Business Results - The Globe and Mail
AbCellera Biologics Reports Q3 2024 Financial Results - TipRanks
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript - Nasdaq
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Abcellera Biologics earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
2.88%
2.65%
자본화:
|
볼륨(24시간):